Biomarkers in pregnant inflammatory bowel disease patients
Research type
Research Study
Full title
Pilot study to assess faecal and serum biomarkers as potential non-invasive inflammatory markers in pregnancy and inflammatory bowel disease.
IRAS ID
153788
Contact name
Helen Steed
Contact email
Sponsor organisation
The Royal Wolverhampton Hospital Trust
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
In pregnancy traditional blood markers of inflammation are elevated related to pregnancy and cannot be used to assess disease activity. Knowing whether there is active disease that requires the introduction of medication that have potential to harm the foetus or success of pregnancy is very important. Currently physicians have to rely on symptoms, which can be very variable or on endosocpic assessment. This inspection of the bowel with a camera also carries risk to the unborn foetus and is not recommended until the second trimester.\nFaecal calprotectin (f-Cp) and S100A12 (f-SA12) are non-invasive stool markers for inflammation in the gut and can be used to distinguish between functional and inflammatory bowel disease(IBD). Serum calprotectin is potentially elevated in pregnancy and currently the usefullness of f-CP is unknown in pregnant women with inflammatory bowel disease.\nThis is a pilot study to take sequential stool and blood samples from pregnant women both with and without inflammatory bowel disease and assess whether there is any value of serum and f-CP and S100A12 as surrogate markers for inflammation in pregnancy.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
15/NW/0934
Date of REC Opinion
26 Nov 2015
REC opinion
Favourable Opinion